Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.57 |
| ▸ | GRM5 | P41594 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | PREP | P48147 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26705429 | 0.94 | CRBN (0.60) | CRBNGRM5L3MBTL1CDK1CCNB1 | |
| SCHEMBL9017627 | 0.79 | MAPK14 (0.55) | L3MBTL1TAS1R3NPC1RAB9ATAS1R1 | |
| SCHEMBL22041505 | 0.77 | RAB9A (0.48) | GRM5L3MBTL1CDK1CCNB1CCNA2 | |
| SCHEMBL1953453 | 0.76 | L3MBTL1 (0.53) | GRM5L3MBTL1CDK1CCNB1CCNA2 | |
| SCHEMBL22688916 | 0.75 | ALDH1A1 (0.54) | CRBNNPC1RAB9AKMT2A | |
| SCHEMBL6366548 | 0.75 | RAB9A (0.49) | CRBNTAS1R3NPC1RAB9ATAS1R1 | |
| SCHEMBL16584089 | 0.75 | POLB (0.55) | L3MBTL1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL10278648 | 0.74 | GRM5 (0.64) | GRM5NPC1RAB9AKMT2A | |
| SCHEMBL13161898 | 0.74 | ALDH1A1 (0.61) | CRBNNPC1RAB9AKMT2A | |
| SCHEMBL1202579 | 0.74 | GAA (0.52) | CRBNPREPNPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12221448-B2 | Selective PI3Kδ inhibitor and use thereof | Tarapeutics Science Inc. (CN) | 2025-02-11 | — | — | US | disclosed |
| EP-3892619-B1 | SELECTIVE PHOSPHATIDYLINOSITOL 3 KINASE (PI3K) INHIBITORS AND USE THEREOF | TARAPEUTICS SCIENCE INC (CN) | 2024-06-26 | — | — | EP | disclosed |
| EP-3892619-B1 | SELECTIVE PHOSPHATIDYLINOSITOL 3 KINASE (PI3K) INHIBITORS AND USE THEREOF | TARAPEUTICS SCIENCE INC (CN) | 2024-06-26 | — | — | EP | disclosed |
| CN-111269231-B | Selective PI3K delta inhibitor and application thereof | 安徽中科拓苒药物科学研究有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20220024931-A1 | SELECTIVE PI3Kdelta INHIBITOR AND USE THEREOF | Tarapeutics Science Inc. (CN) | 2022-01-27 | — | — | US | disclosed |
| US-20220024931-A1 | SELECTIVE PI3Kdelta INHIBITOR AND USE THEREOF | Tarapeutics Science Inc. (CN) | 2022-01-27 | — | — | US | disclosed |
| EP-3892619-A1 | SELECTIVE PI3Ko INHIBITOR AND USE THEREOF | Tarapeutics Science Inc. (CN) | 2021-10-13 | — | — | EP | disclosed |
| EP-3892619-A1 | SELECTIVE PI3Ko INHIBITOR AND USE THEREOF | Tarapeutics Science Inc. (CN) | 2021-10-13 | — | — | EP | disclosed |
| CN-111269231-A | Selective PI3K delta inhibitor and application thereof | 安徽中科拓苒药物科学研究有限公司 | 2020-06-12 | — | — | CN | disclosed |
| WO-2020113642-A1 | SELECTIVE PI3Kδ INHIBITOR AND USE THEREOF | 安徽中科拓苒药物科学研究有限公司 | 2020-06-11 | — | — | WO | disclosed |
| WO-2020113642-A1 | SELECTIVE PI3Kδ INHIBITOR AND USE THEREOF | 安徽中科拓苒药物科学研究有限公司 | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024931-A1 | SELECTIVE PI3Kdelta INHIBITOR AND USE THEREOF | PIK3CA, PIK3CD, PIK3R1 | CRBN 2284/4885GRM5 4170/4885L3MBTL1 1582/4885 |
| US-12221448-B2 | Selective PI3Kδ inhibitor and use thereof | PIK3CA, PIK3CD, PIK3R2 | CRBN 1590/4885GRM5 3733/4885L3MBTL1 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.